Sign in

CIK 0001737287

  • Non-accelerated filer
  • Smaller reporting company

Allogene Therapeutics, Inc.

Sign in to watch
Ticker
ALLO
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Entity type
Operating
EIN
823562771
Phone
+1 650-457-2700
Business address
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
  1. 4 Open-market sale President and CEO sold 23,648 shares at $7.65 ($180,879)
  2. 4 Open-market sale Chief Financial Officer sold 11,469 shares at $7.63 ($87,551)
  3. 4 Open-market sale Chief Technical Officer sold 8,698 shares at $7.63 ($66,388)
  4. 4 Gift Director gave 412,618 shares (gift)
  5. 3 Insider Initial Statement of Ownership
  6. 4 Open-market buy Director bought 15,000 shares at $12.60 ($189,000)
  7. 4 Open-market buy Director bought 155,039 shares at $12.60 ($1,953,491)
  8. 4 Open-market sale EVP of R&D and CMO sold 11,507 shares at $24.35 ($280,185)
  9. 3 Insider Initial Statement of Ownership
  10. 4 Open-market sale General Counsel sold 5,000 shares at $24.77 ($123,845)
  11. 4 Open-market sale Director sold 5,000 shares at $25.54 ($127,700)
  12. 4 Open-market sale Director sold 10,000 shares at an average $23.47 ($234,700)
  13. 4 Open-market sale General Counsel sold 5,000 shares at $21.00 ($104,994)
  14. 4 Grant or award Director acquired 19,362 shares (grant or award)
  15. 4 Derivatives Options or other derivatives
  16. 3 Insider Initial Statement of Ownership
  17. 3 Insider Initial Statement of Ownership
  18. 4 Open-market sale General Counsel sold 5,000 shares at $21.55 ($107,753)
  19. 4 Open-market sale General Counsel sold 5,000 shares at $25.32 ($126,600)
  20. 4 Open-market sale Director sold 9,969 shares at $25.05 ($249,723)

Page 8 of 14 · 275 filings